Article

Adenylate cyclase toxin translocates across target cell membrane without forming a pore.

Institute of Microbiology AS CR vvi, Prague.
Molecular Microbiology (Impact Factor: 5.03). 02/2010; 75(6):1550-62. DOI: 10.1111/j.1365-2958.2010.07077.x
Source: PubMed

ABSTRACT The adenylate cyclase toxin-haemolysin of Bordetella (CyaA) targets CD11b(+) myeloid phagocytes and translocates across their cytoplasmic membrane an adenylate cyclase (AC) enzyme that catalyses conversion of cytosolic ATP into cAMP. In parallel, CyaA acts as a cytolysin forming cation-selective pores, which permeabilize cell membrane and eventually provoke cell lysis. Using cytolytic activity, potassium efflux and patch-clamp assays, we show that a combination of substitutions within the pore-forming (E570Q) and acylation-bearing domain (K860R) ablates selectively the cell-permeabilizing activity of CyaA. At the same time, however, the capacity of such mutant CyaA to translocate the AC domain across cytoplasmic membrane into cytosol of macrophage cells and to elevate cellular cAMP concentrations remained intact. Moreover, the combination of E570Q+K860R substitutions suppressed the residual cytolytic activity of the enzymatically inactive CyaA/OVA/AC(-) toxoid on CD11b-expressing monocytes, while leaving unaffected the capacity of the mutant toxoid to deliver in vitro a reporter CD8(+) T cell epitope from ovalbumin (OVA) to the cytosolic pathway of dendritic cells for MHC class I-restricted presentation and induce in vivo an OVA-specific cytotoxic T cell response. CyaA, hence, employs a mechanism of AC enzyme domain translocation across cellular membrane that avoids passage across the cytolytic pore formed by toxin oligomers.

0 Bookmarks
 · 
128 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to compare two methods for quantification of changes of intracellular potassium concentration (decrease from ∼140 to ∼20 mM) due to action of a pore-forming toxin, the adenylate cyclase toxin (CyaA) from the pathogenic bacterium Bordetella pertussis. CyaA was incubated with stably transfected Chinese hamster ovary cells K1 expressing the toxin receptor CD11b/CD18 and the decrease of potassium concentration in cells was followed by inductively coupled plasma mass spectrometry (ICP-MS). It is shown that this method is superior in terms of sensitivity, accuracy and temporal resolution over the method employing the potassium-binding benzofuran isophthalate-acetoxymethyl ester (PBFI-AM) fluorescent indicator. The ICP-MS procedure was found to be a reliable and straightforward analytical approach enabling kinetic studies of CyaA action at physiologically relevant toxin concentrations (<1000 ng/ml) in biological microsamples.
    Analytical Biochemistry 01/2014; · 2.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The adenylate cyclase toxin-hemolysin (ACT, AC-Hly or CyaA) is a key virulence factor of Bordetella pertussis. It targets bactericidal activities of phagocytes, such as oxidative burst and complement- or antibody-mediated opsonophagocytic killing of bacteria. Through cAMP signaling, CyaA also skews TLR-triggered maturation of dendritic cells, inhibiting proinflammatory IL-12 and TNF-α secretion and enhancing IL-10 production and Treg expansion, likely hampering induction of adaptive immune responses to Bordetella infections. Non-enzymatic CyaA toxoid is a potent protective antigen and adjuvant that boosts immunogenicity of co-administered B. pertussis antigens and improves potency of acellular pertussis (aP) vaccines in mice. This makes CyaA a prime antigen candidate for inclusion into a next generation of aP vaccines. Moreover, recombinant CyaA toxoids were recently shown to be safe in humans in frame of Phase I clinical evaluation of a CyaA-based immunotherapeutic vaccine that induces Th1-polarized CD8(+) cytotoxic T-lymphocyte responses targeting cervical tumors.
    Expert Review of Vaccines 08/2014; · 4.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Whooping cough is a vaccine preventable disease presenting with epidemic cycles linked to natural and/or vaccine-driven evolution of the etiologic agent of the disease, Bordetella pertussis. Adenylate-cyclase hemolysin (AC-Hly) is a major toxin produced by this pathogen that mediates macrophage apoptosis in-vitro and in-vivo. While current acellular pertussis vaccine (APV) formulations do not include AC-Hly, they all contain pertussis toxin (PT) and can comprise filamentous haemagglutinin (FHA), that interacts with AC-Hly, and pertactin (PRN), which has been hypothesized to interact with that toxin as well. We aimed to study the capacity of specific antibodies to inhibit the in-vitro B. pertussis AC-Hly mediated cytotoxicity of J774A.1 murine macrophages in a background of changing bacterial population. We demonstrate that (i) clinical isolates of different type or PRN phenotype are all cytotoxic and lethal in the mouse model of respiratory infection and that lack of PRN production does not impact AC-Hly related phenotypes. (ii) Anti-AC-Hly antibodies inhibit cell lysis whatever the phenotype of the isolate while (iii) Anti-PRN antibodies significantly inhibit cell lysis provided the isolate produces this antigen, which might be relevant in-vivo for APV induced immunity, and (iv) anti-FHA antibodies only inhibit lysis induced by isolates collected in 2012, maybe indicating specific characteristics of epidemic lineages of B. pertussis.
    Microbiology 02/2014; · 3.06 Impact Factor

Full-text (2 Sources)

Download
5 Downloads
Available from
Oct 13, 2014